The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard ...

The data published in NEJM reflect outcomes in the PDAC cohort from the RMC-6236-001 trial (NCT05379985), an open-label, multicenter Phase 1/2 trial evaluating daraxonrasib monotherapy in patients ...

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...

Rash, diarrhea, nausea, and other potential side effects to expect ...

An experimental drug from Revolution Medicines that nearly ​doubled survival time for patients with advanced pancreas cancer ...

The FDA has opened an expanded access program for daraxonrasib, an investigational drug showing encouraging results in pancreatic ductal adenocarcinoma with RAS mutations. Phase I/II trials reported ...

An experimental drug, daraxonrasib from Revolution Medicines, nearly doubles survival time for pancreatic cancer patients in ...

The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

FDA granted rapid expanded access for daraxonrasib in previously treated metastatic PDAC, reflecting urgency and a ...

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, and HRAS. RAS-family mutations are associated with numerous types of cancer.